In The News Posted January 31, 2019 Share Posted January 31, 2019 DAEJEON, South Korea, January 31, 2019 /PRNewswire/ -- IntoCell, Inc., a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies, today announced the publication of its patent application in Korea... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.